VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma ...Middle East

SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary...

Hence then, the article about vvn539 met primary study endpoints in us phase iia clinical study for the treatment of glaucoma was published today ( Monday 05/06/2023 - 03:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma )

Also on site :

• Seizure of Russian-flagged oil tanker: what we know so far
• NYT ‘Connections’ Hints, Clues and Answers Today, Thursday, January 8, 2026
• Nestlé pulls baby milk batches amid safety fears